Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
An in-depth analysis of a cholangiocarcinoma vaccine trial, designed to empower patients with balanced insights into this experimental treatment.
Graeme Holmes
My younger brother Graeme begins this very important yet incredibly difficult page within our foundation
Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
Discover how blocking broken IDH1 with inhibitors is helping cholangiocarcinoma patients. Cholangiocarcinoma Foundation Australia is helping better equip and empower patients to respond more effectively.
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
Explore the latest research and clinical trials involving PARP inhibitors for treating IDH1-mutated intrahepatic cholangiocarcinoma.
Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
An in-depth analysis of a cholangiocarcinoma vaccine trial, designed to empower patients with balanced insights into this experimental treatment.
Graeme Holmes
My younger brother Graeme begins this very important yet incredibly difficult page within our foundation
Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
Discover how blocking broken IDH1 with inhibitors is helping cholangiocarcinoma patients. Cholangiocarcinoma Foundation Australia is helping better equip and empower patients to respond more effectively.
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
Explore the latest research and clinical trials involving PARP inhibitors for treating IDH1-mutated intrahepatic cholangiocarcinoma.
